Flow Cytometry Stem Cell Enumeration Kit Designed to Ease Stem Cell Transplantation
|
By LabMedica International staff writers Posted on 07 Mar 2012 |
|
Image: The BD Stem Cell Enumeration (SCE) Kit (Photo courtesy of BD Biosciences).
A dedicated flow cytometry stem cell enumeration kit is aimed at the rapidly growing stem cell transplantation market.
High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.
To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.
The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.
The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.
Related Links:
BD Biosciences
High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.
To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.
The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.
The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.
Related Links:
BD Biosciences
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Carbapenemase Resistance Detection Assay
NG-TEST® Acineto–5®
New
Rapid Sepsis Test
SeptiCyte RAPID
Latest BioResearch News
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
Channels
Clinical Chemistry
view channel
New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
Predicting which patients with early symptomatic Alzheimer’s disease will decline more rapidly remains a key challenge in both research and patient care. Growing interest in tau biology, along with advances... Read more
Routine Blood Markers Predict Heart Failure Risk in Prediabetes
Heart failure prevention relies on finding high-risk adults before symptoms appear, yet effective stratification remains difficult in routine care. Prediabetes affects an estimated 115.2 million U.... Read more
Molecular Diagnostics
view channel
Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
Burkitt lymphoma is the most common childhood cancer in Africa and progresses rapidly, making fast, accurate diagnosis essential to survival. Although survival can exceed 90% when therapy starts quickly,... Read more
Blood Test Helps Guide Treatment in Older Women with Breast Cancer
Older women with estrogen receptor–positive breast cancer often face difficult decisions about treatment, especially when surgery and radiation can lead to side effects such as scarring, swelling, infection... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Microbiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
Pathology
view channel
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read more
Technology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
Treatment selection for metastatic colorectal cancer often requires knowledge of a tumor’s microsatellite instability (MSI) status. Timely results can help clinicians decide on immunotherapy options.... Read more
